Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 5—May 2019
Research

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Lawrence MbuagbawComments to Author , Lorenzo Guglielmetti, Catherine Hewison, Nyasha Bakare, Mathieu Bastard, Eric Caumes, Mathilde Fréchet-Jachym, Jérôme Robert, Nicolas Veziris, Naira Khachatryan, Tinatin Kotrikadze, Armen Hayrapetyan, Zaza Avaliani, Holger J. Schünemann, and Christian Lienhardt
Author affiliations: St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada (L. Mbuagbaw); Centre for the Development of Best Practices in Health, Yaoundé, Cameroon (L. Mbuagbaw); McMaster University, Hamilton (L. Mbuagbaw, H.J. Schünemann); Centre d'Immunologie et des Maladies Infectieuses, INSERM, Paris (L. Guglielmetti, E. Caumes, J. Robert, N. Veziris); Centre Hospitalier de Bligny, Bris-sous-Forges, France (L. Guglielmetti, M. Fréchet-Jachym); Sorbonne Université, Paris, France (L. Guglielmetti, J. Robert, N. Veziris); Médecins Sans Frontières, Paris (C. Hewison); Janssen Research & Development, LLC, Titusville, New Jersey, USA (N. Bakare); Epicentre, Paris (M. Bastard); Hôpitaux Universitaires de l'Est Parisien, Paris (N. Veziris); Médecins Sans Frontières, Yerevan, Armenia (N. Khachatryan); Médecins Sans Frontières, Tbilisi, Georgia (T. Kotrikadze); National Tuberculosis Control Centre, Yerevan (A. Hayrapetyan); National Centre for Tuberculosis and Lung Disease, Tbilisi (Z. Avaliani); World Health Organization, Geneva, Switzerland (C. Lienhardt); Université de Montpellier, Montpellier, France (C. Lienhardt)

Main Article

Table 3

Multivariable analyses for key outcomes in study of bedaquiline treatment for multidrug-resistant tuberculosis

Covariate Culture conversion at 6 mo, n = 318
 Success, n = 325
 Death, n = 325
Adjusted OR 
(95% CI) p value Adjusted OR (95% CI) p value Adjusted OR (95% CI) p value
Male sex 1.25 (0.65–2.41) 0.499 1.27 (0.74–2.15) 0.382 0.60 (0.24–1.47) 0.264
Age, y 1.01 (0.99–1.04) 0.342 0.99 (0.98–1.01) 0.550 1.05 (1.01–1.09) 0.010
HIV positive 0.42 (0.13–1.39) 0.155 0.35 (0.12–0.99) 0.050 0.97 (0.09–10.05) 0.982
Resistance profile† 0.57 (0.43–0.76) <0.001 0.84 (0.68 −1.04) 0.110 1.14 (0.73–1.79) 0.562
Presence of lung cavitation 0.30 (0.13–0.70) 0.004 0.38 (0.21–0.68) 0.001 5.31 (1.25–22.52) 0.023
Previous use of second-line drugs 0.67 (0.22–2.01) 0.437 0.73 (0.33–1.59) 0.423 1.22 (0.29–5.15) 0.783

*Absence of data on cavitation precluded use of data from South Africa. MDR, multidrug resistant; TB, tuberculosis; XDR, extensively drug resistant.
†Resistance profiles used in this study were MDR TB (reference), MDR TB plus fluoroquinolone, MDR TB plus injectable drugs, and XDR TB.

Main Article

Page created: April 18, 2019
Page updated: April 18, 2019
Page reviewed: April 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external